JP5864856B2 - マトリプターゼタンパク質及びその使用 - Google Patents

マトリプターゼタンパク質及びその使用 Download PDF

Info

Publication number
JP5864856B2
JP5864856B2 JP2010519988A JP2010519988A JP5864856B2 JP 5864856 B2 JP5864856 B2 JP 5864856B2 JP 2010519988 A JP2010519988 A JP 2010519988A JP 2010519988 A JP2010519988 A JP 2010519988A JP 5864856 B2 JP5864856 B2 JP 5864856B2
Authority
JP
Japan
Prior art keywords
cancer
matriptase stem
matriptase
antibody
stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010519988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535506A5 (enExample
JP2010535506A (ja
Inventor
ロフルフフ クフリストイアン
ロフルフフ クフリストイアン
アレクアンデル テルレット ジョナトハン
アレクアンデル テルレット ジョナトハン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
Medarex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex LLC filed Critical Medarex LLC
Publication of JP2010535506A publication Critical patent/JP2010535506A/ja
Publication of JP2010535506A5 publication Critical patent/JP2010535506A5/ja
Application granted granted Critical
Publication of JP5864856B2 publication Critical patent/JP5864856B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2010519988A 2007-08-07 2008-08-07 マトリプターゼタンパク質及びその使用 Expired - Fee Related JP5864856B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96383707P 2007-08-07 2007-08-07
US60/963,837 2007-08-07
PCT/US2008/009512 WO2009020645A2 (en) 2007-08-07 2008-08-07 Matriptase protein and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014155821A Division JP2014223083A (ja) 2007-08-07 2014-07-31 マトリプターゼタンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2010535506A JP2010535506A (ja) 2010-11-25
JP2010535506A5 JP2010535506A5 (enExample) 2011-09-22
JP5864856B2 true JP5864856B2 (ja) 2016-02-17

Family

ID=40239716

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010519988A Expired - Fee Related JP5864856B2 (ja) 2007-08-07 2008-08-07 マトリプターゼタンパク質及びその使用
JP2014155821A Withdrawn JP2014223083A (ja) 2007-08-07 2014-07-31 マトリプターゼタンパク質及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014155821A Withdrawn JP2014223083A (ja) 2007-08-07 2014-07-31 マトリプターゼタンパク質及びその使用

Country Status (7)

Country Link
US (1) US8420091B2 (enExample)
EP (1) EP2185933B1 (enExample)
JP (2) JP5864856B2 (enExample)
AU (1) AU2008284271B2 (enExample)
DK (1) DK2185933T3 (enExample)
ES (1) ES2550754T3 (enExample)
WO (1) WO2009020645A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011063127A1 (en) 2009-11-18 2011-05-26 University Of Medicine And Dentistry Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
US20120294800A1 (en) * 2009-01-07 2012-11-22 University Of Medicine And Dentistry Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
US8420084B2 (en) * 2009-03-05 2013-04-16 Medarex, Inc. Fully human antibodies specific to CADM1
US9849192B2 (en) 2009-11-18 2017-12-26 Rutgers, The State University Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
CA2887037A1 (en) 2012-10-02 2014-04-10 Rutgers, The State University Of New Jersey Specific delivery of toxins conjugated with antibodies to activated matriptase
EA201690806A1 (ru) * 2013-11-25 2016-09-30 Оксфорд Байотерапьютикс Лтд. Антитела
KR102441107B1 (ko) * 2014-11-07 2022-09-13 후지쿠라 가세이 가부시키가이샤 데옥시하이푸신·신타제 유전자를 지표로서 사용하는 동맥 경화 및 암의 검출 방법
AU2017235571B2 (en) 2016-03-18 2024-05-16 Georgetown University Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022821B1 (en) * 1998-02-20 2006-04-04 O'brien Timothy J Antibody kit for the detection of TADG-15 protein
US5972616A (en) 1998-02-20 1999-10-26 The Board Of Trustees Of The University Of Arkansas TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas
JP4778617B2 (ja) 1999-03-12 2011-09-21 ジョージタウン ユニバーシティ マトリプターゼ、セリンプロテアーゼおよびその応用
US7030231B1 (en) 1999-09-30 2006-04-18 Catalyst Biosciences, Inc. Membrane type serine protease 1 (MT-SP1) and uses thereof
EP1226150A4 (en) * 1999-10-20 2005-05-25 Univ Arkansas TADG-15: EXTRACELLULAR SERINE PROTEASE EXPRESSED IN CARCINOMA
US6447978B1 (en) 1999-12-03 2002-09-10 Kodak Polychrome Graphics Llc Imaging member containing heat switchable polymer and method of use
JP2003521920A (ja) 2000-02-03 2003-07-22 コルバス・インターナショナル・インコーポレイテッド 膜貫通セリンプロテアーゼをコードしている核酸分子、コードされたタンパク質、およびそれらに基づく方法
US6903201B2 (en) 2001-01-05 2005-06-07 Curagen Corporation Proteins and nucleic acids encoding same
AU2002305052A1 (en) 2001-03-13 2002-09-24 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
AU2002254357A1 (en) 2001-03-22 2002-10-08 Dendreon Corporation Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
US7105333B2 (en) 2001-03-27 2006-09-12 Deadreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
KR20040080940A (ko) 2001-05-14 2004-09-20 덴드레온 코포레이션 트랜스막 세린 프로테아제 10을 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
US7019019B2 (en) 2002-12-23 2006-03-28 Dendreon Corporation Matriptase inhibitors and methods of use
US8239547B2 (en) 2004-07-09 2012-08-07 Telefonaktiebolaget Lm Ericsson (Publ) Method and arrangement for providing different services in a multimedia communication system
CA2592249C (en) 2004-12-20 2014-07-29 Amgen Fremont Inc. Binding proteins specific for human matriptase
WO2006090389A2 (en) 2005-02-24 2006-08-31 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
WO2007047796A2 (en) * 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use

Also Published As

Publication number Publication date
AU2008284271B2 (en) 2014-03-13
DK2185933T3 (en) 2015-10-26
US20100285017A1 (en) 2010-11-11
AU2008284271A1 (en) 2009-02-12
JP2014223083A (ja) 2014-12-04
US8420091B2 (en) 2013-04-16
EP2185933B1 (en) 2015-10-07
WO2009020645A2 (en) 2009-02-12
WO2009020645A3 (en) 2009-05-07
JP2010535506A (ja) 2010-11-25
EP2185933A2 (en) 2010-05-19
ES2550754T3 (es) 2015-11-12

Similar Documents

Publication Publication Date Title
JP5945381B2 (ja) タンパク質
US20120282177A1 (en) ROR1 as Therapeutic and Diagnostic Target
JP2023011880A (ja) 癌治療および判断ターゲットとしてのｌｙ７５
US8540998B2 (en) Methods for treating cancer using ephrin type-A receptor 10 antibodies conjugated to cytotoxic agents
JP5864856B2 (ja) マトリプターゼタンパク質及びその使用
US20190310255A1 (en) Proteins
US8084034B2 (en) Proteins
JP6523968B2 (ja) 治療的及び診断的標的としての不活性Ｎ−アセチル化−α−結合型酸性ジペプチダーゼ−様タンパク質２（ＮＡＡＬＡＤＬ２）
US20110229480A1 (en) Pta072 protein
EP2447719A1 (en) Proteins
US8652478B2 (en) Method for treating cancer by administering antibody to ephrin type-A receptor 7
US20150210770A1 (en) Therapeutic and diagnostic target
US20120058131A1 (en) Pta089 protein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130312

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130912

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140401

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20140425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140731

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140908

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20141107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151023

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151225

R150 Certificate of patent or registration of utility model

Ref document number: 5864856

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees